title: Ceftolozane-Tazobactam Pharmacokinetics in a Critically Ill Patient on Continuous Venovenous Hemofiltration.
abstract: Extended-infusion ceftolozane-tazobactam treatment at 1.5 g every 8 h was used to treat multidrug-resistant Pseudomonas aeruginosa in a critically ill patient on continuous venovenous hemofiltration. Serum drug concentrations were measured at 1, 4, 5, 6, and 8 h after the start of infusion. Prefilter levels of ceftolozane produced a maximum concentration of drug (Cmax) of 38.57 μg/ml, concentration at the end of the dosing interval (Cmin) of 31.63 μg/ml, time to Cmax (Tmax) of 4 h, area under the concentration-time curve from 0 to 8 h (AUC0-8) of 284.38 μg · h/ml, and a half-life (t1/2) of 30.7 h. The concentrations were eight times the susceptibility breakpoint for the entire dosing interval.
authors.affiliation: University of Maryland Medical Center, Baltimore, Maryland, USA.
authors.forename: Wesley D
authors.initials: WD
authors.lastname: Oliver
authors.affiliation: University of Maryland Medical Center, Baltimore, Maryland, USA.
authors.forename: Emily L
authors.initials: EL
authors.lastname: Heil
authors.affiliation: University of Maryland School of Pharmacy, Baltimore, Maryland, USA jgonzale@rx.umaryland.edu.
authors.forename: Jeffrey P
authors.initials: JP
authors.lastname: Gonzales
authors.affiliation: University of Maryland School of Pharmacy, Baltimore, Maryland, USA.
authors.forename: Shailly
authors.initials: S
authors.lastname: Mehrotra
authors.affiliation: University of Maryland School of Medicine, Baltimore, Maryland, USA.
authors.forename: Kathryn
authors.initials: K
authors.lastname: Robinett
authors.affiliation: University of Maryland School of Medicine, Baltimore, Maryland, USA.
authors.forename: Paul
authors.initials: P
authors.lastname: Saleeb
authors.affiliation: Hartford Hospital, Hartford, Connecticut, USA.
authors.forename: David P
authors.initials: DP
authors.lastname: Nicolau
mesh_terms: D000900:Anti-Bacterial Agents / Q000493:pharmacokinetics* / Q000627:therapeutic use; D002511:Cephalosporins / Q000493:pharmacokinetics* / Q000627:therapeutic use*; D016638:Critical Illness; D024901:Drug Resistance, Multiple, Bacterial; D006440:Hemofiltration; D006801:Humans; D007362:Intensive Care Units; D008297:Male; D008826:Microbial Sensitivity Tests; D008875:Middle Aged; D010397:Penicillanic Acid / Q000031:analogs & derivatives* / Q000493:pharmacokinetics / Q000627:therapeutic use; D011446:Prospective Studies; D016459:Prosthesis-Related Infections / Q000188:drug therapy / Q000382:microbiology; D011552:Pseudomonas Infections / Q000188:drug therapy*; D011550:Pseudomonas aeruginosa / Q000187:drug effects*; D000078142:Tazobactam
chemical_list: D000900:Anti-Bacterial Agents; D002511:Cephalosporins; C519491:ceftolozane; D010397:Penicillanic Acid; D000078142:Tazobactam